Keyphrases
Liraglutide
100%
End-stage Renal Disease
75%
Type 2 Diabetes Mellitus (T2DM)
55%
Glycemic Efficacy
50%
Continuous Glucose Monitoring
50%
Placebo-controlled
50%
Group-randomized Trial
50%
Dialysis
50%
Investigator-initiated
50%
Type 2 Diabetic Patients
50%
Hypoglycemic Events
33%
Dialysis-dependent
30%
Placebo
21%
Placebo Groups
16%
Glucose Variability
16%
Control Subjects
15%
Maximum Tolerated Dose
13%
Insulin
13%
Antidiabetic Treatment
13%
Linear Mixed Model
13%
Glycated Hemoglobin A1c
8%
Group Standard
8%
Monitoring Data
8%
Hypoglycemia Risk
8%
Blinded Treatment
8%
AIMS™
8%
Coefficient of Variation
8%
Glucose Values
8%
Medtronic
8%
Gastrointestinal Side Effects
5%
Primary Outcome Measure
5%
Blood Glucose Measurement
5%
Treatment Dose
5%
Normal Renal Function
5%
Once-daily
5%
Placebo Treatment
5%
Mg Treatment
5%
Glycemic Control
5%
Titration
5%
Vomiting
5%
Nausea
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
83%
End Stage Renal Disease
75%
Antidiabetic Agent
46%
Mixed Model
13%
Hemoglobin A1c
8%
Hypoglycemia
8%
Maximum Tolerated Dose
8%
Gastrointestinal Symptom
5%
Nausea and Vomiting
5%
